Cargando…

Toxin-Based Targeted Therapy for Malignant Brain Tumors

Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandramohan, Vidyalakshmi, Sampson, John H., Pastan, Ira, Bigner, Darell D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287048/ https://www.ncbi.nlm.nih.gov/pubmed/22400035 http://dx.doi.org/10.1155/2012/480429

Ejemplares similares

EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery
por: Bao, Xuhui, et al.
Publicado: (2016)

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2013)

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors
por: Yu, Xin, et al.
Publicado: (2019)

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2019)

Antitumor efficacy of D2C7-(scdsFv)-PE38KDEL, a novel immunotoxin targeting EGFRwt and EGFRvIII, by convection-enhanced delivery in orthotopic brain tumor mouse models
por: Bao, Xuhui, et al.
Publicado: (2013)

A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system
por: Choi, Bryan D., et al.
Publicado: (2013)

Imaging of Convection Enhanced Delivery of Toxins in Humans
por: Mehta, Ankit I., et al.
Publicado: (2011)

SYST-12 D2C7 CAR: A NOVEL CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOMA AND BRAIN METASTASES
por: Wilkinson, Daniel, et al.
Publicado: (2022)

SYST-14 D2C7 CAR EFFECTIVELY AND SAFELY TREATS EGFRWT AND EGFRVIII-EXPRESSING TUMORS FOLLOWING INTRACRANIAL ADMINISTRATION
por: Wilkinson, Daniel, et al.
Publicado: (2023)

Monitoring Radiographic Brain Tumor Progression
por: Mehta, Ankit I., et al.
Publicado: (2011)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
por: Keir, Stephen T., et al.
Publicado: (2018)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors
por: Kanaly, Charles W., et al.
Publicado: (2011)

Targeted Toxins in Brain Tumor Therapy
por: Li, Yan Michael, et al.
Publicado: (2010)

Enzyme Redesign Guided by Cancer-Derived IDH1 Mutations
por: Reitman, Zachary J., et al.
Publicado: (2012)

Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas
por: Flores, Catherine, et al.
Publicado: (2015)

Targeting malignant B cells with an immunotoxin against ROR1
por: Baskar, Sivasubramanian, et al.
Publicado: (2012)

Myeloablative Temozolomide Enhances CD8(+) T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice
por: Sanchez-Perez, Luis A., et al.
Publicado: (2013)

Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies
por: Müller, Fabian, et al.
Publicado: (2017)

Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors
por: Ashley, David M., et al.
Publicado: (1997)

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma
por: Miao, Hongsheng, et al.
Publicado: (2014)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Oncolytic poliovirus directs tumor antigen presentation and T cell activation in vitro
por: Brown, Michael C, et al.
Publicado: (2015)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

Effect of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors from a Mathematical Model
por: Pak, Youngshang, et al.
Publicado: (2014)

Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy
por: Dieffenbach, Michael, et al.
Publicado: (2020)

Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient’s Bedside to Evaluation in Preclinical Models
por: Leshem, Yasmin, et al.
Publicado: (2019)

AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival
por: Di, Chunhui, et al.
Publicado: (2017)

Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
por: Wang, Chunguang, et al.
Publicado: (2016)

Targeting Malignant Brain Tumors with Antibodies
por: Razpotnik, Rok, et al.
Publicado: (2017)

Aberrant Otx2 Expression Enhances Migration and Induces Ectopic Proliferation of Hindbrain Neuronal Progenitor Cells
por: Wortham, Matthew, et al.
Publicado: (2012)

Photodynamic Therapy for Malignant Brain Tumors
por: AKIMOTO, Jiro
Publicado: (2016)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells()
por: Cui, Bo, et al.
Publicado: (2010)

Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer
por: Xie, Liyi, et al.
Publicado: (2018)

Targeting Toxins toward Tumors
por: Franzyk, Henrik, et al.
Publicado: (2021)

Targeting Oncometabolism to Maximize Immunotherapy in Malignant Brain Tumors
por: Bernstock, Joshua D., et al.
Publicado: (2022)

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
por: Mason-Osann, Emily, et al.
Publicado: (2015)

Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sj5uvppfks8thcorbkg0suuk97